Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 17;9(11):2494.
doi: 10.3390/cells9112494.

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Wout Devlies  1   2 , Markus Eckstein  3 , Alessia Cimadamore  4 , Gaëtan Devos  1 , Lisa Moris  1   2 , Thomas Van den Broeck  1 , Rodolfo Montironi  4 , Steven Joniau  1 , Frank Claessens  2 , Thomas Gevaert  5
Affiliations
Review

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Wout Devlies et al. Cells. .

Abstract

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

Keywords: androgen receptor; biomarker; histology; mCRPC; prostate cancer; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clinical pathway to metastatic castration resistant prostate cancer (mCRPC) with the current treatment options.
Figure 2
Figure 2
Overview major affected pathways in mCRPC and their possible actionability.
Figure 3
Figure 3
Possible benefits of molecular profiling in mCRPC management. When progressive disease appears, discussions upon next line treatments should be based upon all available data to allocate a patient tailored follow-up treatment.
See this image and copyright information in PMC

References

    1. Sehgal P.D., Bauman T.M., Nicholson T.M., Vellky J.E., Ricke E.A., Tang W., Xu W., Huang W., Ricke W.A. Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer. Hum. Pathol. 2019;89:99–108. doi: 10.1016/j.humpath.2019.04.009. - DOI - PMC - PubMed
    1. EAU Guidelines . EAU Annual Congress. EAU Guidelines Office; Amsterdam, The Netherlands: 2020.
    1. Mottet N., Gillessen S., Mottet N. EAU Guidelines: Prostate Cancer|Uroweb. [(accessed on 7 August 2020)];2020 Available online: https://uroweb.org/guideline/prostate-cancer/
    1. Francini E., Gray K.P., Shaw G.K., Evan C.P., Hamid A.A., Perry C.E., Kantoff P.W., Taplin M.-E., Sweeney C.J. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019;22:420–427. doi: 10.1038/s41391-018-0121-2. - DOI - PMC - PubMed
    1. de Bono J.S., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K.N., Sartor O., Agarwal N., Olmos D., et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020;382:2091–2102. doi: 10.1056/NEJMoa1911440. - DOI - PubMed

Publication types

MeSH terms